SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001072613-18-000264
Filing Date
2018-04-04
Accepted
2018-04-04 16:42:28
Documents
1
Group Members
CLARUS VENTURES II GP, L.P.CLARUS VENTURES II, LLCDENNIS HENNERKURT WHEELERNICHOLAS GALAKATOSNICHOLAS SIMONROBERT LIPTAK

Document Format Files

Seq Description Document Type Size
1 CLARUS LIFESCIENCES II, L.P. CATABASIS PHARMACEUTICALS, INC. SCHEDULE 13DA - AME clarus2-catabasis13d_18193.htm SC 13D/A 266910
  Complete submission text file 0001072613-18-000264.txt   268706
Mailing Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142
Business Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142 617-949-2200
Clarus Lifesciences II, L.P. (Filed by) CIK: 0001431443 (see all company filings)

IRS No.: 261856183 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address ONE KENDALL SQUARE BLDG. 1400E, SUITE B14202 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE BLDG. 1400E, SUITE B14202 CAMBRIDGE MA 02139 617-349-1971
CATABASIS PHARMACEUTICALS INC (Subject) CIK: 0001454789 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88910 | Film No.: 18737752
SIC: 2834 Pharmaceutical Preparations